Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5760131 | 0.89 | KDM4E (0.39) | ALDH1A1GAAKDM4EHRH2HRH1 | |
| SCHEMBL13483418 | 0.89 | KDM4E (0.39) | ALDH1A1GAAKDM4EHRH2HRH1 | |
| SCHEMBL12724660 | 0.89 | KDM4E (0.39) | ALDH1A1GAAKDM4EHRH2HRH1 | |
| SCHEMBL13683427 | 0.81 | ALDH1A1 (0.46) | ALDH1A1HTTHTR1AGAAXBP1 | |
| SCHEMBL12772416 | 0.81 | ALDH1A1 (0.46) | ALDH1A1HTTHTR1AGAAXBP1 | |
| SCHEMBL14503937 | 0.81 | ALDH1A1 (0.46) | ALDH1A1HTTHTR1AGAAXBP1 | |
| SCHEMBL12724663 | 0.80 | CACNA1H (0.37) | GAAHRH1CHRM2 | |
| SCHEMBL12449643 | 0.79 | HRH3 (0.45) | ALDH1A1GAAKDM4EHRH3HPGD | |
| SCHEMBL12449640 | 0.79 | HRH3 (0.45) | ALDH1A1GAAKDM4EHRH3HPGD | |
| SCHEMBL12721 | 0.79 | HRH3 (0.45) | ALDH1A1GAAKDM4EHRH3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002233-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2021-01-07 | — | — | US | disclosed |
| US-10766865-B2 | PKM2 modulators and methods for their use | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200237766-A1 | PKM2 ACTIVATORS IN COMBINATION WITH REACTIVE OXYGEN SPECIES FOR TREATMENT OF CANCER | SUMITOMO PHARMA ONCOLOGY, INC. | 2020-07-30 | — | — | US | disclosed |
| US-10472328-B2 | PKM2 modulators and methods for their use | TOLERO PHARMACEUTICALS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190119219-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2019-04-25 | — | — | US | disclosed |
| US-10207996-B2 | PKM2 modulators and methods for their use | TOLERO PHARMACEUTICALS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170015631-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2017-01-19 | — | — | US | disclosed |
| US-20170015631-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2017-01-19 | — | — | US | disclosed |
| US-9394257-B2 | PKM2 modulators and methods for their use | TOLERO PHARMACEUTICALS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150344436-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2015-12-03 | — | — | US | disclosed |
| US-20120053170-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS | SANOFI (FR) | 2012-03-01 | — | — | US | disclosed |
| US-7932257-B2 | Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7605176-B2 | β-ketoamide compounds with MCH antagonistic activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-20 | — | — | US | disclosed |
| US-7402580-B2 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | disclosed |
| US-20070027166-A1 | Pyrazolo pyrimidines useful as aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766865-B2 | PKM2 modulators and methods for their use | PDK1, PDK2, PKM | ALDH1A1 2333/4885HTT 2553/4885HTR1A 2251/4885 |
| US-20120053170-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS | NAMPT, NNT, NQO1 | ALDH1A1 195/4885HTT 1916/4885HTR1A 4259/4885 |
| US-20070027166-A1 | Pyrazolo pyrimidines useful as aurora kinase inhibitors | AURKA, AURKB, AURKC | ALDH1A1 3764/4885HTT 4789/4885HTR1A 3051/4885 |
| US-10472328-B2 | PKM2 modulators and methods for their use | PDK1, PDK2, PKM | ALDH1A1 2333/4885HTT 2553/4885HTR1A 2251/4885 |
| US-20170015631-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PDK2, PKM | ALDH1A1 2333/4885HTT 2553/4885HTR1A 2251/4885 |
| US-10207996-B2 | PKM2 modulators and methods for their use | PDK1, PDK2, PKM | ALDH1A1 2333/4885HTT 2553/4885HTR1A 2251/4885 |
| US-20200237766-A1 | PKM2 ACTIVATORS IN COMBINATION WITH REACTIVE OXYGEN SPECIES FOR TREATMENT OF CANCER | PDK1, PDK2, PCK2 | ALDH1A1 978/4885HTT 4528/4885HTR1A 4621/4885 |
| US-20190119219-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PDK2, PKM | ALDH1A1 2333/4885HTT 2553/4885HTR1A 2251/4885 |
| US-20210002233-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PDK2, PKM | ALDH1A1 2333/4885HTT 2553/4885HTR1A 2251/4885 |
| US-20150344436-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PDK2, PKM | ALDH1A1 2333/4885HTT 2553/4885HTR1A 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.